Sou Hu Cai Jing·2025-08-19 10:48Core Viewpoint - *ST SAILONG (002898) has shown a significant increase in stock price, closing at 15.59 yuan, up 4.98% as of August 19, 2025, indicating positive market sentiment despite declining financial performance [1] Financial Performance - The latest quarterly report for *ST SAILONG shows total revenue of 54.09 million yuan, a year-on-year decrease of 22.16% [1] - The net profit attributable to shareholders is 1.04 million yuan, down 163.94% year-on-year [1] - The non-recurring net profit is 1.11 million yuan, reflecting a substantial decrease of 228.58% year-on-year [1] - Key financial ratios include a current ratio of 0.975, a quick ratio of 0.629, and a debt-to-asset ratio of 38.15% [1] Market Activity - The stock experienced a trading volume of 33,600 lots and a transaction amount of 51.56 million yuan [1] - The net inflow of main funds was 11.53 million yuan, accounting for 22.36% of the transaction amount [1] - Large orders saw a net inflow of 13.74 million yuan, representing 26.64% of the transaction amount, while small orders had a net outflow of 6.19 million yuan, making up 12.01% [1] Company Overview - SAILONG Pharmaceutical Group Co., Ltd. was established in 2002 and is located in Zhuhai City, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 176 million yuan and has made investments in 12 enterprises [2] - SAILONG has participated in 6 bidding projects and holds 32 trademark registrations and 38 patents, along with 39 administrative licenses [2]